FLIR Stock Falls, Admits 'Decelerating' Demand For Temperature Screening
Is the boom going to bust for temperature screening? FLIR disappointed investors with their Q2 results acknowledging decelerating demand for temperature screening.
In this report, we examine why FLIR is already on the downswing of its Elevated Skin Temperature (EST) boom and why customers are delaying and calling off their orders.
These delays have caused FLIR to withdraw a previously issued financial guidance for the remainder of 2020, meant to be announced with these results, signaling their postponed bookings to the end of 2020 and uncertainty going forward for investors.
Overview ** *******
**** ***. ********* ********* ******* **** ********* * ***** ******* ************* ****.
******* *** **** ******* ******* ** despite ***********:
******** *** *** ******* **** $***.* million, ********** **** *** ***** **** quarter.
*** ****** ********* *** ******** ******* on *** *******'* ****** ****, ******* it *** ****** ** ****** ** the ********** ******* *** ** **** commercial ******.
** **** ****** * ******** ** operational ********** ** ******* **** ****** and ********** *****, ***** *** ******* the ****.
Withdrew **** **** ********
**** ******** * ********** ****** ******** for *** **** **** ****** ******** 31, **** "*** ** *** *********** uncertainty ********* ** *** *****-** ********".
Stock ***** ***** ~**%
** * ******, ****'* (******: ****) ***** ***** **** *******:
'Decelerating' ******* ******
*** *******'**** ********* ********, *** ***** *** ****** ******** throughout ****, **** ******* ******.
*** *** ****** ********* *** ******** have ******* ******* ** **% **** the ***** *******:
***** ******* ************* $*** ******* ** EST ****** ****** *** ***** *******, we've ******** ************* $** ******* ****** the ****** *******....
******* *****, *** ******* ******** **** nearly $*** ******* ** **:
** ******* ***** $** ******* ** EST-related ******** ** *** ****** *******.
** ******** ******* ****** ****** *** early ******** ****** ******* ***:
** *** ***** **** ** *** pandemic, ******* **** ** ***, ** saw ****** *****.
****** **** **** * **** ***** of *********** ****** **** ********* *** non ********* ********** ****** ******* ****** for *** ********* ** **** ******** strategies ** ***** ****** ** ******* and ** ****** ** ********.
****, ********* ***** ****** * "******** approach" *** ******** ******* ********** ** EST ********, **********, ** **** ***** eventual ***********:
****** *** ****** **** ** *** quarter, ******* ********* ***** ******** ***** behavior, ****** ******* ** ***** ********* our ********** ** * ******* ***** to **** ***** ******** ** ******* of ******** ***** ***** ********** **** deployment.
**** **** ******** ******** ** ********** led ** * ************ ** *** demand ** *** ******* **********.
Demand ** ******* ****, '*********'
*** *** ******** ******** ***** ********* for *** ******* ********* ******** ***** forward ** ****, **** ****** ******** to "*********" ** ***** ***** ******:
** ** **** ***** ** *** second **** ** *** **** ** expect ****** *** *** ************ ** stabilize, ****** ** ****** ***** **** we *********** ** *** ****** *******.
3 ****** ** **** **********
****'* *** ********* * ****** **** initial ******** ** **** ******** *** constrained **********:
******** *** ****** ***** *** *** in **** ** * ******. ***** was *** ******* **** ** ****** that **** ******* *** *** ** the ***** ******* *** **** ******...
** ** *** **** ******* ****** of ******, ** ** ********* ** the **** ****, ***** $*** ******* in *** **** *** ** **. And **** ** ** ******* *** second *******... *** *** ******** ******* changed ******** ** ****, **** * very, **** **** ********** ** ********* across *** ***** ** ********** ** a **** **** *******, ****** *** essential **********. ** ***** ************* *************, large ********** **** ****** *************, ********* or **** ******** *************...
** ** *** *** ****** ***** a *** *** *** ****** **** as ***** ********* **** ********** ******* orders *** **** ********** **** ********** diligence ** *** ****'** *** *** technology, **** ***********, *** ****'** ********* it **** ***** ********** *** ************ they ** -- ** *** ** have * **** *********.
*** *** **'** **** ** ** this ***** *******, ***** ***** *********, again, **** ** **** **** ***** and ********** ***************, *** ****** ********* about ****, ***** ** ** **** do ***** ***************.
*** ****'* *** ******* **'** ****** now. ************* ***** **** **** *******, how *** ** *** ******** ** the ****** ** * **** **** deliberate ************** ** **** ***** ********* that *** * **** ** *** they ** ********.
Weaker *** **** ** ******* *********** ******?
*** ******** *** ** ******* **** is ****** *** **** *** **** or *** ******* *********** ******.
** *** *** ****, ****'* ******** are ********* *** *** ******* *** been ********** ************ ** *** **** market ****. **** ***** ** * shift ** *****-**** ********, **** ** temperature ******* ** ****-******* ** ****. FLIR *** ** ********* ** ***** segments ** ** *** ****** ****** shift ** ***** ********, **** ***** lose *** **********.
** *** ***** ****, ** *** seeing ********** ******* *** ******** ** the ******* ****** *** *********** ********* products ** ****** ****** **** ************* about *** ***** ******* ***** *** what *********** *********** **** ****. ******, FLIR's *** *********** ** *** ***** rush ******** ** **** ******** ********** is **** ** *** ****** ****.
**********, **** ***** **** ********* **** earlier ** ****, ******* *** **** ** ********:
**'** **** ******** **** ** **** at *** ******** **** **'** ******* around ** ** ** ******* ***** how **** **** ****** ******** ** revenue. ** *** **** ** ***** get * ********** ****** ** ********. But ** *** ******** ** *** virus ******* ***** ******** ***** ** canceled *** *** **** **** *******."
Vote / ****
*********** ****** ****** ** ******** ** IPVM
*** *********** ****** ******* ******... **** of ****** ** ********* **** ***** but *** **** **** **** ** actual ************ ******* ** * ***** proprietary ********* **** **** ******* **** more ****** **** **** **** ** not ***, ** **.
**** ** ****** ** ********* **** about *** *** **** **** **** do ****** ************ ******* ** * magic *********** ********* **** **** ******* look **** ****** **** **** **** is *** ***, ** **.
**** ***** ****** ****** ** *** business ****. * ***** *** ****** is ******* **** **** ** *** buyers ** ***** ******** ********** **** that **** ***'* ****** ****, *** they ** *** ** * **** show. ****, ** ********* **** *** the ********** ** ***** **** ***** and **** ********* ****** **** ******* product (****) **** ** ****** **** accurate *******? * ***** *** ***** argue **** ***** ** ****, ** is **** ** ***** **** *** taking *** ******* ****, *** * think **** **** ********** ***** ** far ***** ***** ** *** *****.
**** *** **** **** ****** *** providing *** ******** **** ***** **** an ******** ******* **** **** **** revenue, *** **** **** ** **** of * ******** **** *** ****** application ****. **** *** **** **** equipped ** ******* ** *** ******** of **** ****, **** ****** ****** net *******, *** *********** ***** *******.
***** ***, * *** ** ******* in * *** **** ***** ********, mainly *** ****** ******. *** ****** case *** ** ******* *** *********** did *** ********* ** ******* ****** on ***** ********. * ***** **** businesses **** ***** ******* ****'* ******** but **** *** ****** **** ** prove ********* ** **** ** * lawsuit. *'** **** ***** ** * Wal-Mart ******* ** *** *** * think *** *********** ******* ******** ** the **** ****** ** ***** **** be ********* *********** *** ****** *** way ********** ***** ** *********.
***** * ********** *** ******, ** was ******** ******** **** ** *** success ** *** *** ****.
*** **** ********** **** ***** *** EST ****** ***** *** ****** **** from ********* ********* ** **** ** some ** ***** **** *********** **** measurement ********* *** *******. *** *** phase ***** ** ****** *** *** FLIR ** ***** ********* *** ****** get ******* *** *********** **** **** new ********* ****** **** ******** *** do *** ****** ** ****.
**** **** ***** ********** ********** ** their ******** *****, ***** *** ** no ****** ****** * ******** *****, it *** **** ****** **** *** Instruments *****.
****'** **** ******* ************ *** ****-***** TruWitness ****** ** *** **** *******, just ** ** ******* **** *** market *** **** ******* ***** ******** be *******. ** *** ****, * can't ***** ****, ********** *** **** compatible **** ******** ***, ***** *** not **** ***********. ** *** ***** hand, ** *** ******* *** ****, why *** ** ***** *** ** capitalize ** **?
**** ***** ****** **** **** ** similar ** *** ***** ********* "**** to *** ******", ****** **** **** short *****. **** ** ******* *** in ****** **** ** *** ****** becomes ********.
*** ******. *** **** ** *** bottom *** * *********** ** * things :
*. ****** ********** *** ********* ** scale **** ***** ************* ** ***** costs.
*. * ******** ** *********** ****** to *** ****** *****.
*** ***** ****** ** ********, ** created ***** ********* *** ** **** of *********.
"*** ***** ****** ** ********, ** created ***** ********* *** ** **** of *********." (********* ** *** '**** to *** ****** *******)
***** - *** *** ********* ** unforeseen ******** ****** - ***** ***** not **** **** ********* ** ****** - ******* **** **** **** ** inventory, **** ***** *** ****** ** cheaper, ****-**** ********* */**** *** *****.
***** ** *****?
* ** ********** ** **** ********** - *** ******** **** ****.
***** - *** *** ********* ** unforeseen ******** ******
** *** **** ** *** **** this ******** * ******* ***** *** a *** ************* **** **** ** better ******** *** *** **** ***... assuming ** ***'* *** ***** **** the **** *** ******** ******* **** happened **** ****.
****** ****'* * ****** *** **.
****** ***** *** ******** ********** ** business ************ ****** *** ******** ** use ****** **** *********, ******** *** cost ********* *********.
** ** *******, *** ******** ** cameras *** ****** *** **** ***** oil ****** ** *** ******-***** **** rush. *** **** ********* ****** ** head ***** ***** ** ******** ******* by ***** *** ********. **** ******** makers *** *** **** ******* ********* fever ******* *** ************* **** **** need ** **** ****.
** ******** **** ** **** **** and ***** ** ******** ************, **** would ******* **** ***** ****** ********* non-contact ************ ***** **** ******* ** policy *** ********* ** *** ******* these *****.
** ***** *******, **** ****'* **** a **** *** *** **** ** presence, ************ ***** **** *** *** ridiculous ******.
***** **** **** * ***** ******* is ** ****** ******* ******* *******.
****, *********, *** *********** **** **** demand *** *** ******* ** * fast ************* *****
** **** * ********* *** ** against ***** *******? :) *******, * see **** **** **** *** ****** about *** ****** ***** ** **** goes **. *** ** *** ***** are ** ***** *** *** **** in ***** *** *** *** ***** high *** ** ***** ***** ***. To **, **** ** * ******* sign *** ***** ****** *****, ** line **** **** **** *** ****** in ***** * ****** *******.
* ***'* ***** *** **** ************, because * ******* ********* *** ******** to *****-**** ********* *** **** ** not ** ********* **** ****** ** dropping. ********* ********, ** ** ****, the *********** **** ***** **** ** a **** *** ********* ******* ****** 3-4 ****** **** **** ** ****** distributed ** *-* ****** ***** **** which **** ********* ******* ** *** end ** **** *** ****** **** to ****** ** * ***** **** of **** ** ******* ****** *** EST ******* ****.
** *-* ******, ** **** *** if ***** * ****** **** ****. We **** *** ** ***** *** enough ********* ** ***** *** ******* that *** ****** *******. ** **** see **** ****** **** *** ********** and **** *********** **** **** ********* the *******. ** **** *** **** if ******* *** ****** *** ***** to *** *** ******** ** ******* stimulus ** ***. ***'* *** ****** the ******* ** *** ***** ** mutate **** ********* ***** **** *** done ******* **** *** ***** ***** protein ****** ** **** **********. **** businesses *** *****-** ********* ********** ***, if **, **** *********** ** **** need ** **** ** ** ********?
****** *** *** **** ** ** and **** **** *** **** *** years ** *** ******** *** ********* landscape ******.
****** *** *** **** ** ** and **** **** *** **** *** years
**** *** *****? ***, * **** you *** ***** ******* ****, ** me, ***** ***** **** *********** *** not **** ******.
* **** ***'* *** ****-****** ****** for **** ******* **** * ******* is ****** ***********.
******** **** **** ****-******** ******** *********, there *** * ********* **** **** was ** ********* *****-**** *** ***** would **** ****** ****** ** *****'* remorse. ******, ** *** ********* **** could ** ** ******** ** ***** measures ** ***** *** **** **** the ******** ***** ** ***. *** fear, ********* *** *********** *** ********* warranted, *** *** ** *** **** extended ******* ******** ******** ** **** statistics *** ********* ******* **** *** not ************** ** **** ******.
******** ******* ********/******/***., ****** ***** ******* and *********** ******** ********, ********** *** distancing, ***** ************** ********/*******/*** *****, *** fitting ********* **** ****** *** ** conduct ********* ** * **** **** cost ********* *** ******** ******** ** proving *** ****.
******* ***** ** ** ****** ** with * *********** ** ****-********** ************. EST *** ****** **** **** * sliver; * ****** **** ** *** have * ********** **** ****** *******, at ****.
*** *** ** *** “********** ****” could ** **** ******* ** *** DVTEL/Security *******.
*** ****** ** “*** ****** *** buy” ***** **** **** *** ****** FLIR **** ****’* ***** *** ******* over *** ****** **** *** *********** worked ****** ** ******** ** ****.